Klemens Budde
Cited by
Cited by
Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
H Northrup, DA Krueger, S Roberds, K Smith, J Sampson, B Korf, ...
Pediatric neurology 49 (4), 243-254, 2013
Angiotensin II type 1–receptor activating antibodies in renal-allograft rejection
D Dragun, DN Müller, JH Bräsen, L Fritsche, M Nieminen-Kelhä, ...
New England Journal of Medicine 352 (6), 558-569, 2005
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo …
JJ Bissler, JC Kingswood, E Radzikowska, BA Zonnenberg, M Frost, ...
The Lancet 381 (9869), 817-824, 2013
Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
DA Krueger, H Northrup, S Roberds, K Smith, J Sampson, B Korf, ...
Pediatric neurology 49 (4), 255-265, 2013
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
F Vincenti, S Friman, E Scheuermann, L Rostaing, T Jenssen, ...
American Journal of Transplantation 7 (6), 1506-1514, 2007
Everolimus in patients with autosomal dominant polycystic kidney disease
G Walz, K Budde, M Mannaa, J Nürnberger, C Wanner, C Sommerer, ...
New England Journal of Medicine 363 (9), 830-840, 2010
Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report
M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ...
Therapeutic drug monitoring 41 (3), 261-307, 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ...
The Lancet 393 (10184), 1937-1947, 2019
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
K Budde, T Becker, W Arns, C Sommerer, P Reinke, U Eisenberger, ...
The Lancet 377 (9768), 837-847, 2011
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts
N Lachmann, PI Terasaki, K Budde, L Liefeldt, A Kahl, P Reinke, ...
Transplantation 87 (10), 1505-1513, 2009
CC chemokine receptor 5 and renal-transplant survival
M Fischereder, B Luckow, B Hocher, RP Wüthrich, U Rothenpieler, ...
The Lancet 357 (9270), 1758-1761, 2001
Biomarkers in acute kidney injury–pathophysiological basis and clinical performance
EV Schrezenmeier, J Barasch, K Budde, T Westhoff, KM Schmidt‐Ott
Acta physiologica 219 (3), 556-574, 2017
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients
K Budde, RL Schmouder, R Brunkhorst, B Nashan, PW Lu, T Mayer, ...
Journal of the American Society of Nephrology 13 (4), 1073-1083, 2002
Neutrophil gelatinase‐associated lipocalin: pathophysiology and clinical applications
E Singer, L Markó, N Paragas, J Barasch, D Dragun, DN Müller, K Budde, ...
Acta physiologica 207 (4), 663-672, 2013
Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions
A Sharif, M Hecking, APJ De Vries, E Porrini, M Hornum, ...
American Journal of Transplantation 14 (9), 1992-2000, 2014
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial
T van Gelder, HT Silva, JW de Fijter, K Budde, D Kuypers, G Tyden, ...
Transplantation 86 (8), 1043-1051, 2008
Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations
H Northrup, ME Aronow, EM Bebin, J Bissler, TN Darling, PJ de Vries, ...
Pediatric Neurology 123, 50-66, 2021
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction
F Diekmann, K Budde, F Oppenheimer, L Fritsche, HH Neumayer, ...
Transplantation 78 (2), 115, 2004
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation
L Rostaing, D Cantarovich, G Mourad, K Budde, P Rigotti, C Mariat, ...
Transplantation 79 (7), 807-814, 2005
Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study
K Budde, J Curtis, G Knoll, L Chan, HH Neumayer, Y Seifu, M Hall, ...
American Journal of Transplantation 4 (2), 237-243, 2004
The system can't perform the operation now. Try again later.
Articles 1–20